Antibe Therapeutics (ATBPF) Short Interest Ratio & Short Volume $0.22 0.00 (0.00%) (As of 11/4/2024 ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartEarningsHeadlinesShort Interest Antibe Therapeutics Short Interest DataAntibe Therapeutics (ATBPF) has a short interest of 65,100 shares. This marks a 0.00% change in short interest from the previous month. The short interest ratio (days to cover) is 0.0, indicating that it would take 0.0 days of the average trading volume of 27,352 shares to cover all short positions.Current Short Interest65,100 sharesPrevious Short Interest65,100 sharesChange Vs. Previous MonthNo ChangeDollar Volume Sold Short$14,035.56Short Interest Ratio0.0 Days to CoverLast Record DateOctober 15, 2024Outstanding Shares52,981,000 sharesPercentage of Shares Shorted0.12%Today's Trading Volume0 sharesAverage Trading Volume27,352 sharesToday's Volume Vs. Average0% Short Selling Antibe Therapeutics? Sign up to receive the latest short interest report for Antibe Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartATBPF Short Interest Over TimeATBPF Days to Cover Over TimeATBPF Percentage of Float Shorted Over Time Ad Porter & CompanyThe Final FrontierAnd a lot of powerful investors would rather this exposé never saw the light of day. I suspect they’ll attempt to discredit it, tar and feather it, and convince you not to watch it. That’s because it tells the shocking truth about the current AI mania… and why investors in big tech companies like Nvidia, Meta, Alphabet, and Microsoft could be in for a whole world of pain.Here’s the full story for you. Antibe Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 10/15/202465,100 shares $14,035.56 No ChangeN/A0 $0.22 9/30/202465,100 shares $14,035.56 No ChangeN/A0 $0.22 9/15/202465,100 shares $14,035.56 No ChangeN/A0 $0.22 8/31/202465,100 shares $14,035.56 No ChangeN/A0 $0.22 8/15/202465,100 shares $14,061.60 No ChangeN/A0 $0.22 7/31/202465,100 shares $14,061.60 No ChangeN/A0 $0.22 Get the Latest News and Ratings for ATBPF and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Antibe Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 7/15/202465,100 shares $14,061.60 No ChangeN/A0 $0.22 6/30/202465,100 shares $14,035.56 No ChangeN/A0 $0.22 6/15/202465,100 shares $14,061.60 No ChangeN/A0 $0.22 5/31/202465,100 shares $14,061.60 No ChangeN/A0 $0.22 5/15/202465,100 shares $14,061.60 No ChangeN/A0 $0.22 4/30/202465,100 shares $14,035.56 No ChangeN/A0 $0.22 4/15/202465,100 shares $14,035.56 +1,934.4%N/A0.7 $0.22 3/31/20243,200 shares $1,070.40 -64.0%N/A0.1 $0.33 3/15/20248,900 shares $2,891.61 -73.1%N/A0.1 $0.32 2/29/202433,100 shares $23,653.26 +234.3%N/A0.5 $0.71 2/15/20249,900 shares $6,811.20 No ChangeN/A0.6 $0.69 1/15/202410,400 shares $8,112.00 -9.6%N/A1.4 $0.78 12/31/202311,500 shares $7,843.00 +121.2%N/A0.7 $0.68 12/15/20235,200 shares $3,571.88 -17.5%N/A1.1 $0.69 11/30/20236,300 shares $3,433.50 -54.0%N/A0.8 $0.55 11/15/202313,700 shares $7,521.30 +17.1%N/A0.1 $0.55 10/31/202311,700 shares $5,382.00 -27.8%N/A0.2 $0.46 10/15/202316,200 shares $5,799.60 +211.5%N/A1.7 $0.36 9/30/20235,200 shares $1,863.06 -24.6%N/A0.2 $0.36 9/15/20236,900 shares $2,829.00 -76.4%N/A0.3 $0.41 8/31/202329,200 shares $11,554.44 -22.8%N/A1.1 $0.40 8/15/202337,800 shares $15,498.00 +563.2%N/A1.5 $0.41 7/31/20235,700 shares $2,053.14 -8.1%N/A0.4 $0.36 7/15/20236,200 shares $2,156.98 No ChangeN/A2.8 $0.35 6/30/20236,200 shares $2,170.00 -7.5%N/A2.6 $0.35 6/15/20236,700 shares $2,517.19 -71.7%N/A1.6 $0.38 5/31/202323,700 shares $8,752.41 +203.9%N/A1.3 $0.37 5/15/20237,800 shares $2,934.36 -27.8%N/A0.6 $0.38 4/30/202310,800 shares $4,342.68 -6.9%N/A3.1 $0.40 4/15/202311,600 shares $4,637.68 -78.6%N/A3.6 $0.40 3/31/202354,100 shares $23,766.13 -1.3%N/A2.5 $0.44 3/15/202354,800 shares $20,643.16 +260.5%N/A1.2 $0.38 2/28/202315,200 shares $5,668.08 -37.5%N/A1.7 $0.37 2/15/202324,300 shares $10,529.19 +22.7%N/A4.9 $0.43The Final Frontier (Ad)And a lot of powerful investors would rather this exposé never saw the light of day. I suspect they’ll attempt to discredit it, tar and feather it, and convince you not to watch it. That’s because it tells the shocking truth about the current AI mania… and why investors in big tech companies like Nvidia, Meta, Alphabet, and Microsoft could be in for a whole world of pain.Here’s the full story for you. 1/31/202319,800 shares $8,401.14 +94.1%N/A0.8 $0.42 1/15/202310,200 shares $5,115.81 -56.8%N/A4.3 $0.50 12/30/202223,600 shares $7,622.80 -23.1%N/A2.5 $0.32 12/15/202230,700 shares $11,666.00 +44.8%N/A2.8 $0.38 11/30/202221,200 shares $7,420.00 +32.5%N/A3.2 $0.35 11/15/202216,000 shares $5,912.00 +3.9%N/A1.3 $0.37 10/31/202215,400 shares $5,998.30 +12.4%N/A3.1 $0.39 10/15/202213,700 shares $5,555.35 -8.7%N/A3 $0.41 9/30/202215,000 shares $6,718.50 -41.4%N/A1.1 $0.45 9/15/202225,600 shares $12,170.24 -13.8%N/A2.8 $0.48 8/31/202229,700 shares $14,362.92 -15.1%N/A2.3 $0.48 8/15/202235,000 shares $17,570.00 -39.2%N/A3.3 $0.50 7/31/202257,600 shares $25,920.00 -26.9%N/A20.6 $0.45 7/15/202278,800 shares $37,248.76 +3.8%N/A17.1 $0.47 6/30/202275,900 shares $35,832.39 -5.8%N/A5.2 $0.47 6/15/202280,600 shares $38,833.08 +2.8%N/A6.3 $0.48 5/31/202278,400 shares $42,696.64 +5.0%N/A6.2 $0.54 5/15/202274,700 shares $39,591.00 +48.8%N/A6.2 $0.53 4/30/202250,200 shares $28,011.60 +8.9%N/A7 $0.56 4/15/202246,100 shares $27,293.51 +45.9%N/A3.7 $0.59 3/31/202231,600 shares $20,066.00 +3.3%N/A2.4 $0.64 3/15/202230,600 shares $17,448.12 -23.7%N/A1.6 $0.57 2/28/202240,100 shares $23,454.49 +74.4%N/A1.1 $0.58 2/15/202223,000 shares $12,811.00 +57.5%N/A1.5 $0.56 1/31/202214,600 shares $7,678.14 +630.0%N/A0.2 $0.53 1/15/20222,000 shares $1,115.80 -66.1%N/A0.1 $0.56 12/31/20215,900 shares $3,043.81 -65.7%N/A0.1 $0.52 12/15/202117,200 shares $8,536.36 -71.4%N/A0.4 $0.50 11/30/202160,100 shares $32,737.67 -41.1%N/A1.6 $0.54 11/15/2021102,000 shares $72,644.40 -42.3%N/A0.7 $0.71 10/29/2021176,800 shares $114,725.52 +665.4%N/A1.2 $0.65 10/15/202123,100 shares $18,225.90 +725.0%N/A0.4 $0.79 9/30/20212,800 shares $2,640.40 +180.0%N/A0 $0.94 9/15/20211,000 shares $948.40 +11.1%N/A0 $0.95 8/31/2021900 shares $900.00 -96.4%N/A0 $1.00 8/13/202124,700 shares $25,935.00 -88.2%N/A0.1 $1.05 7/30/2021208,400 shares $561,638.00 +10.7%N/A6.6 $2.70 7/15/2021188,200 shares $513,409.60 -0.1%N/A9.6 $2.73 6/30/2021188,300 shares $559,251.00 -3.7%N/A5.8 $2.97 6/15/2021195,500 shares $602,218.20 -8.2%N/A5.5 $3.08 5/28/2021212,900 shares $724,924.50 +8.0%N/A11 $3.41 5/14/2021197,200 shares $646,816.00 -5.6%N/A8.2 $3.28 4/30/2021208,900 shares $714,458.89 +6.8%N/A5.8 $3.42 4/15/2021195,600 shares $708,072.00 -12.6%N/A9.5 $3.62 3/31/2021223,700 shares $883,615.00 +41.5%N/A1.8 $3.95 3/15/2021158,100 shares $623,388.30 -54.4%N/A3.2 $3.94 2/26/2021346,600 shares $1.50 million +439.9%N/A2 $4.34 2/12/202164,200 shares $301,098.00 -17.3%N/A0.5 $4.69 1/29/202177,600 shares $219,297.60 +21.1%N/A1.8 $2.83 12/31/202028,600 shares $89,518.00 No ChangeN/A0.5 $3.13The Final Frontier (Ad)And a lot of powerful investors would rather this exposé never saw the light of day. I suspect they’ll attempt to discredit it, tar and feather it, and convince you not to watch it. That’s because it tells the shocking truth about the current AI mania… and why investors in big tech companies like Nvidia, Meta, Alphabet, and Microsoft could be in for a whole world of pain.Here’s the full story for you. 11/30/202030,700 shares $9,513.93 +332.4%N/A0.1 $0.31 11/15/20207,100 shares $2,188.93 -64.5%N/A0.1 $0.31 10/30/202020,000 shares $4,800.00 No ChangeN/A0.2 $0.24 10/15/202020,000 shares $5,342.00 +52.7%N/A0.2 $0.27 9/30/202013,100 shares $3,445.30 No ChangeN/A0 $0.26 8/31/20201,300 shares $388.96 -93.1%N/A0 $0.30 8/14/202018,900 shares $5,934.60 -44.9%N/A0 $0.31 7/31/202034,300 shares $9,569.70 +2,350.0%N/A0.1 $0.28 7/15/20201,400 shares $408.52 -92.4%N/A0 $0.29 6/30/202018,300 shares $5,574.18 -36.2%N/A0 $0.30 6/15/202028,700 shares $10,705.10 +135.3%N/A0 $0.37 5/29/202012,200 shares $3,782.00 +281.3%N/A0.1 $0.31 5/15/20203,200 shares $1,856.00 -98.3%N/A0 $0.58 4/30/2020191,600 shares $101,548.00 +787.0%N/A0.6 $0.53 4/15/202021,600 shares $10,584.00 -83.4%N/A0.1 $0.49 3/31/2020130,400 shares $70,416.00 -52.7%N/A0.3 $0.54 3/13/2020275,700 shares $137,850.00 +58.3%N/A0.6 $0.50 2/28/2020174,200 shares $64,454.00 +60.9%N/A0.8 $0.37 2/14/2020108,300 shares $49,818.00 -18.0%N/A0.2 $0.46 1/31/2020132,000 shares $62,040.00 +28.4%N/A0.4 $0.47 1/15/2020102,800 shares $49,344.00 -47.6%N/A0.3 $0.48 12/31/2019196,000 shares $76,440.00 -3.1%N/A1.4 $0.39 ATBPF Short Interest - Frequently Asked Questions What is Antibe Therapeutics' current short interest? Short interest is the volume of Antibe Therapeutics shares that have been sold short but have not yet been covered or closed out. As of October 15th, investors have sold 65,100 shares of ATBPF short. Learn More on Antibe Therapeutics' current short interest. How does Antibe Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Antibe Therapeutics: vTv Therapeutics Inc. (2.25%), Immix Biopharma, Inc. (2.75%), Carisma Therapeutics, Inc. (4.92%), Provectus Biopharmaceuticals, Inc. (0.00%), Unicycive Therapeutics, Inc. (1.24%), DURECT Co. (3.30%), ProPhase Labs, Inc. (1.08%), Clene Inc. (2.63%), Rallybio Co. (2.66%), Earth Science Tech, Inc. (0.00%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.14 billion), AppLovin Co. ($3.15 billion), Paychex, Inc. ($2.69 billion), Nu Holdings Ltd. ($2.48 billion), Cencora, Inc. ($2.24 billion), International Paper ($2.04 billion), Tractor Supply ($1.96 billion), Coinbase Global, Inc. ($1.93 billion), Moderna, Inc. ($1.91 billion), and SoFi Technologies, Inc. ($1.84 billion). View all of the most shorted stocks. What does it mean to sell short Antibe Therapeutics stock? Short selling ATBPF is an investing strategy that aims to generate trading profit from Antibe Therapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Antibe Therapeutics? A short squeeze for Antibe Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ATBPF, which in turn drives the price of the stock up even further. How often is Antibe Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ATBPF, twice per month. The most recent reporting period available is October, 15 2024. More Short Interest Resources from MarketBeat Related Companies vTv Therapeutics Short Interest Data Immix Biopharma Short Interest Data Carisma Therapeutics Short Interest Data Provectus Biopharmaceuticals Short Interest Data Unicycive Therapeutics Short Interest Data DURECT Short Interest Data ProPhase Labs Short Interest Data Clene Short Interest Data Rallybio Short Interest Data Earth Science Tech Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (OTCMKTS:ATBPF) was last updated on 11/4/2024 by MarketBeat.com Staff From Our Partners2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...Investing Daily | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredElection warning coming true… If you missed it, my emergency election broadcast is now available - watch it before it's too late.Porter & Company | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Antibe Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Antibe Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
